Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the country’s PDP programme, providing access to around 70% of public-sector demand.
Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the country’s PDP programme, providing access to around 70% of public-sector demand.
<iframe src="https://hindustansphere.com/embed/cluster/f53b93202f74fef3b05c3dba180409e7e55825b7" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil"></iframe>
